The stroke clinical program is probably too far ahead of HIE for HIE to be approved first.
So very unlikely to be awarded a priority review voucher.
Still great endorsement/validation from the FDA for the pre-clinical work done to-date.
Ann: FDA Grants Rare Pediatric Disease Designation For HIE, page-9
Add AGN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
79.0¢ |
Change
0.010(1.28%) |
Mkt cap ! $100.4M | |||
| Open | High | Low | Value | Volume |
| 78.0¢ | 80.5¢ | 78.0¢ | $71.40K | 90.43K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | 78.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 80.5¢ | 2444 | 1 |
View Market Depth
| Last trade - 15.55pm 23/08/2024 (20 minute delay) ? |
| AGN (ASX) Chart |